Dublin, Sept. 10, 2021 (GLOBE NEWSWIRE) -- The "Global Viral Vector Production (Research-use) Market Size, Share & Trends Analysis Report by Vector Type (Adenovirus, AAV, Lentivirus), by Application, ...
As a lab within the Cooperative Center of Excellence in Hematology (CCEH) at Fred Hutch, the Vector Production core assists investigators with the design, construction, and/or production of viral ...
The viral vector production market size was valued at $1.1 billion in 2022, and is estimated to reach $6.1 billion by 2032, growing at a CAGR of 18.8% from 2023 to 2032. Briefly introduce the concept ...
Production of viral vectors requires a holistic view of the product, including its manufacturing process and its ultimate end use. Viral vectors must be free of contaminants, such as adventitious ...
Lentiviral vectors have emerged as indispensable tools in gene therapy, offering the ability to integrate therapeutic genes into both dividing and non-dividing cells. Their unique capacity to achieve ...
Despite the undeniable ability of viral vectors to deliver genetic payloads, and despite the incredible promise of this approach to treat a vast variety of diseases—including metabolic, cardiovascular ...
The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
VectorBuilder’s manufacturing center in Guangzhou, China, will work with Univercells Technologies to develop and optimize platform processes for the production of custom viral vectors for cell and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback